Investor
Tap into the exponential growth of the RNA market
It's easier to just be first
We founded FBB Biomed because we saw the potential of RNA for medicine. COVID-19 made that potential evident to everyone.
Effective therapies only emerge after effective diagnostics. Case in point: drugs for HIV/AIDS. FBB Biomed's technology platform will be the first to enable personalized diagnostics and therapeutics based on ancestral genes.
Company profile
-
U.S. Veteran-owned
-
Delaware C corporation
-
Operating out of Iowa
-
Supported by the great State of Iowa
-
Loyal VC portfolio company
-
Capital structure: Common stock only
Proprietary AI-powered RNA platform
RNA's abundance in human tissue makes it the ideal foundation for early-stage, highly accurate, truly personalized diagnostics.
Owing to its functional and regulatory role in molecular processes, RNA makes real-time diagnostics possible, as opposed to mere risk stratification.
By leveraging existing genomic sequencing infrastructure and the latest bioinformatics software, we have built a proprietary AI-powered RNA platform with diagnostic as well as therapeutic applications.